CD22
免疫毒素
单克隆抗体
抗体
抗体-药物偶联物
内化
内吞作用
抗原
细胞毒性T细胞
化学
皂甙
药品
癌症研究
免疫学
生物
细胞
药理学
生物化学
体外
出处
期刊:Int J Biologicals
日期:2017-12-10
卷期号:40 (6): 289-293
标识
DOI:10.3760/cma.j.issn.1673-4211.2017.06.007
摘要
The CD22 molecule is restrictively expressed on the surface of B-lineage cells, and can enter cells through constitutive internalization once it binds its ligand or antibody. Due to its characteristic, CD22 molecule becomes an attractive biological target for treatment of hematologic malignancies by antibody-drug conjugates (ADCs). ADC consists of strong cytotoxic drugs conjugated to specific antibodies via linker. It takes advantage of the specificity and endocytosis of monoclonal antibody to guide drugs directly into target cells. In this article, the characteristic of targets, antibodies, linkers, and drugs of CD22-targeting ADCs, as well as research progress of CD22-targeting ADCs which entered clinical trials in recent years are summarized.
Key words:
Antigens, CD22; Immunotoxins; Lymphoma, B-cell
科研通智能强力驱动
Strongly Powered by AbleSci AI